48 results
8-K
AUTL
Autolus Therapeutics plc
1 Apr 24
Departure of Directors or Certain Officers
7:06am
earlier death, resignation or removal.
Mr. Bonney, age 65, possesses over 30 years of operational, commercial and senior management experience … and qualified, or until his earlier death, resignation or removal.
Dr. Rao, age 55, has served as Chief Medical Officer of Sitryx, a biopharmaceutical company
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
of the programmed T cell and triggers cell death. We use the RQR8 safety switch in our AUTO4, AUTO5 and AUTO6NG programs.
Rapamycin Safety Switch (RapaCasp9 … rapamycin. Once administered, rapamycin heterodimerises caspase 9 via FRB and FKBP to activate a cell death cascade and selectively eliminate
8-K/A
EX-99.1
AUTL
Autolus Therapeutics plc
15 Mar 24
Results of Operations and Financial Condition
4:21pm
high risk of infection. In fact, many of these patients do pass away as a consequence of sepsis in general as a major cause of death. And as you can
8-K
EX-99.2
AUTL
Autolus Therapeutics plc
14 Mar 24
Results of Operations and Financial Condition
12:32pm
disposition Developing Next Generation Programmed T Cell Therapies 11 127/153 (83%) enrolled patients received obe-cel* Discontinued n (%) 26 (17) Death 15 (10
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
13 Feb 24
Regulation FD Disclosure
4:06pm
n (%) 26 (17) Death 15 (10) Manufacturing-related 7 (5) Adverse event 2 (1) Physician decision 1 (0.7) Progressive disease 1 (0.7) *Seven patients … extension phase in R/R B-CLL and B-NHL, data cut-off date September 13, 2023. *Patient death unrelated to obe-cel and without relapse or disease progression
8-K
qfjo hv6wpxz
10 Jan 24
Departure of Directors or Certain Officers
3:12pm
8-K
plqfsy02kj qbq4q
22 Dec 23
Departure of Directors or Certain Officers
8:24am
8-K
EX-99.2
00p6y7hyam ps0npfuan
11 Dec 23
Regulation FD Disclosure
8:31am
8-K
EX-99.1
ugn9uoa
11 Dec 23
Regulation FD Disclosure
8:31am
10-Q
EX-10.1
bplqdmwl ry1d
9 Nov 23
Quarterly report
4:18pm
6-K
EX-99.3
2t2eiizlrki99775qa
3 Aug 23
Index to Condensed Consolidated Financial Statements
4:32pm
6-K
w3vdg0ipz0 b0
20 Jun 23
Current report (foreign)
4:59pm
6-K
EX-99.3
ueso1igyx4lhdyxhm
4 May 23
Index to Condensed Consolidated Financial Statements
4:04pm
6-K
EX-1
fclopdz4pm9ix517 u4s
1 Jul 22
Current report (foreign)
5:15pm
6-K
imylb0vx
15 Nov 21
Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director
12:00am
6-K
0jacgp
15 Sep 21
Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors
4:30pm
6-K
EX-1
a8e0iafg
30 Jun 21
Annual Report and Accounts
6:05am